Never miss an issue of Master Investor Magazine – sign-up now for free! |
Omega Diagnostics (LON:ODX) has announced the appointment of three new dedicated distributors in Ghana, Zambia and Zimbabwe for its VISITECT CD4 HIV test. All three countries require product registration, which has also commenced. Once completed, this will allow business to business sales to commence through the Company’s distributors.
“I am pleased to see our commercialisation plan for CD4 taking shape as this is key part of our strategy to delivering shareholder value,” commented Omega CEO Colin King. “This also provides further evidence that our CD4 test (the world’s first true point-of-care test) will make a significant difference to people living with HIV in resource-poor environments.”
Omega shares rose 0.7p on the news, to 15.7p (as at 09:47 BST).